Australia - angielski - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - promethazine hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; lactose monohydrate; povidone; maize starch; macrogol 200; titanium dioxide; indigo carmine; purified water; industrial methylated spirit - allergies: treatment of allergic conditions including some allergic reactions to drugs, urticaria, contact dermatitis, and allergic reactions to insect bites and stings. upper respiratory tract: relief of excesive secretion in the upper respiratory tract as a result of hayfever and allergic rhinitis. nausea and vomiting: antiemetic in vomiting of various causes, including post-operative vomiting, irradiation sickness, drug induced nausea, and motion sickness. sedation: for short term use on the advice of a doctor or pharmacist.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - abacavir sulfate, quantity: 351 mg (equivalent: abacavir, qty 300 mg); zidovudine, quantity: 300 mg; lamivudine, quantity: 150 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate type a; microcrystalline cellulose; purified water; titanium dioxide; hypromellose; indigo carmine; iron oxide yellow; macrogol 400 - trizivir is indicated in antiretroviral therapy for the treatment of human immunodeficiency virus (hiv) infected adults and adolescents over the age of 12 years. trizivir should not be administered to adults and adolescents who weigh less than 40kg because it is a fixed dose tablet, and the dose cannot be adjusted for this patient population.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - lamivudine, quantity: 150 mg; zidovudine, quantity: 300 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 4000 - combivir is indicated for use alone or in combination with other antiretroviral therapies in the treatment of hiv infection.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

aubex pharma pty ltd - flecainide acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: hydrogenated vegetable oil; purified water; microcrystalline cellulose; pregelatinised maize starch; croscarmellose sodium; magnesium stearate - bpa-flecainide is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although bpa-flecainide may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, bpa-flecainide should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of bpa-flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,bpa-flecainide tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous (available in other brands) therapy or conversion by other means.,prescribers should also consult the "special warnings and precautions for use" section of this product information.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

aubex pharma pty ltd - flecainide acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; magnesium stearate; microcrystalline cellulose; hydrogenated vegetable oil; purified water; croscarmellose sodium - bpa-flecainide is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although bpa-flecainide may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, bpa-flecainide should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of bpa-flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,bpa-flecainide tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous (available in other brands) therapy or conversion by other means.,prescribers should also consult the "special warnings and precautions for use" section of this product information.

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

redox limited - aluminium phosphide - tablet (inc. pellet, bolus, suppository, capsule) - aluminium phosphide mineral-aluminium active 560.0 g/kg - mixed function pesticide - stored barley seed | stored breakfast cereal | stored bulk stock feed | stored cereal grain | stored cereal produce | stored coc - stored commodity pests

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sunzon international inc - aluminium phosphide - tablet (inc. pellet, bolus, suppository, capsule) - aluminium phosphide mineral-aluminium active 330.0 g/kg - insecticide - food product/commodity | grain handling machinery | shed,factory,warehouse or other building | stored barley seed | stored break - angoumois grain moth | bean weevil | cadelle | cigarette beetle | cockroach | coffee bean weevil | confused flour beetle | dried fruit beetle | flat grain beetle | granary weevil | hide or skin beetle | indian meal moth | lesser grain borer | maize weevil | mediterranean flour moth | merchant grain beetle | mottled grain moth | mouse - mus spp. | psocids or booklouse | raisin moth | rat | redlegged ham beetle | rice weevil | rust-red flour beetle | sawtoothed grain beetle | spider beetle | stored product mite | tobacco moth | tropical warehouse moth | warehouse beetle | dermestes ater | dermestes maculatus | grain borer | large cockroach | small cockroach | tobacco beetle

Australia - angielski - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - vildagliptin, quantity: 50 mg; metformin hydrochloride, quantity: 1000 mg - tablet, film coated - excipient ingredients: iron oxide yellow; titanium dioxide; hypromellose; macrogol 4000; hyprolose; purified talc; magnesium stearate - for patients with type 2 diabetes mellitus (t2dm):,galvumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients whose diabetes is not adequately controlled on metformin hydrochloride alone or who are already treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. treatment should not be initiated with this fixed-dose combination.,galvumet is indicated in combination with a sulfonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulfonylurea.,galvumet is indicated as add-on to insulin as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 850 mg; vildagliptin, quantity: 50 mg - tablet, film coated - excipient ingredients: macrogol 4000; hypromellose; iron oxide yellow; magnesium stearate; titanium dioxide; hyprolose; purified talc - for patients with type 2 diabetes mellitus (t2dm):,galvumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients whose diabetes is not adequately controlled on metformin hydrochloride alone or who are already treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. treatment should not be initiated with this fixed-dose combination.,galvumet is indicated in combination with a sulfonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulfonylurea.,galvumet is indicated as add-on to insulin as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 500 mg; vildagliptin, quantity: 50 mg - tablet, film coated - excipient ingredients: hypromellose; macrogol 4000; titanium dioxide; magnesium stearate; purified talc; iron oxide yellow; iron oxide red; hyprolose - for patients with type 2 diabetes mellitus (t2dm):,galvumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients whose diabetes is not adequately controlled on metformin hydrochloride alone or who are already treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. treatment should not be initiated with this fixed-dose combination.,galvumet is indicated in combination with a sulfonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulfonylurea.,galvumet is indicated as add-on to insulin as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.